FDA Approves Ozempic for Chronic Kidney Disease in Type 2 Diabetes Patients

The expanded approval allows Ozempic to reduce risks of kidney failure, cardiovascular death, and disease progression in patients with diabetes and chronic kidney disease.

The FDA has approved Ozempic, a GLP-1 receptor agonist, for reducing kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
This decision is based on the FLOW trial, which showed Ozempic reduced kidney disease events by 24% and cardiovascular-related deaths by 29% compared to a placebo.
The trial also demonstrated slower kidney function decline and an 18% reduction in major cardiovascular events like heart attacks among Ozempic users.
Approximately 37 million U.S. adults suffer from chronic kidney disease, with diabetes being a leading risk factor; 40% of type 2 diabetes patients are affected.
Novo Nordisk's announcement follows similar approval in the EU and highlights the growing use of GLP-1 drugs for broader health benefits beyond diabetes and weight loss.